Recognition of the patient with acquired hemophilia (AH) and confirmation of the diagnosis have proven to be very challenging [1]. The demographics of AH have been established primarily through data collected from small clinical studies or from national surveillance registries, which are both encumbered by possible referral bias. Thus, the published prevalence (the proportion of the population found to have AH) for the disease likely represents a significant underestimate. Overall, AH has an estimated prevalence of 1.48 cases per million per year, and a reported mortality between 9% and 22% [2,3]. Recent data generated within the UK and Wales national health systems affirm the prevalence to be 1.3-1.5 per million per year [4,5]. Despite its low prevalence, the condition imposes significant clinical, medical, and economic challenges because its dramatic complications are frequently life threatening and management of bleeding events is expensive.Age of onset for AH is distributed in a biphasic pattern, with a small peak in young individuals, primarily postpartum women and those with autoimmune diseases, and the major peak in those aged 60-80 years of either sex. AH is uncommon in children under the age of 16 years (estimated at 0.045/ million/year), and may be underdiagnosed in the very elderly older than age 85 years (estimated at 14.7/million/year) [3]. Of the 172 patients in the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) dataset, 63% were aged 65 years to less than 85 years, and an additional 22% were aged 85 years and older [3]. The European Acquired Haemophilia Registry (EACH2), which includes 501 patients with AH from 13 European countries, has also reported a bimodal age distribution, with a small peak occurring in younger women, mainly those with peripartum AH (median age 33.9 years) [6]. In the largest published population series, 50-60% of diagnosed individuals who developed AH were previously healthy with no identified underlying disease state [2,3,7]. The clinical conditions most consistently associated with AH have included pregnancy; evolving or pre-existing autoimmune diseases; hematologic and solid tumor malignancies; and administration of certain medications (e.g. penicillin, sulfonamides, interferon-α, etc.) [8].